Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
In patients with unresectable advanced pancreatic cancer, non-inferiority of TS-1 monotherapy
and superiority of GEM + TS-1 combination therapy to gemcitabine (GEM) will be verified using
survival time.